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DOI 10.1016/j.ccr.2011.10.022SUMMARYNLRP12 is a member of the intracellular Nod-like receptor (NLR) family that has been suggested to downre-
gulate the production of inflammatory cytokines, but its physiological role in regulating inflammation has not
been characterized. We analyzed mice deficient in Nlrp12 to study its role in inflammatory diseases such as
colitis and colorectal tumorigenesis. We show that Nlrp12-deficient mice are highly susceptible to colon
inflammation and tumorigenesis, which is associated with increased production of inflammatory cytokines,
chemokines, and tumorigenic factors. Enhanced colon inflammation and colorectal tumor development in
Nlrp12-deficient mice are due to a failure to dampen NF-kB and ERK activation in macrophages. These
results reveal a critical role for NLRP12 in maintaining intestinal homeostasis and providing protection
against colorectal tumorigenesis.INTRODUCTION
Inflammation is generally considered to be a host protective
response against infection and injury (Medzhitov, 2008).
However, uncontrolled inflammation is a major risk factor for
the development of cancer (Grivennikov et al., 2010). Colorectal
cancer is the third most common form of cancer and the second
leading cause of cancer-related death in developed countries
(Eaden et al., 2001; Ekbom et al., 1990; Itzkowitz and Yio,
2004). Notably, patients with inflammatory bowel diseases
(IBD) such as Crohn’s disease and ulcerative colitis are at
increased risk for the development of colorectal cancer (Fiocchi,
1998). Although the precisemolecular mechanism of IBD-related
colorectal tumor formation is incompletely understood, it is
widely viewed that cytokines, chemokines, matrix degrading
enzymes, and growth factors produced during chronic inflam-Significance
Colorectal cancer is the third most common form of cancer and
oped countries. Chronic inflammation shapes the tumorigenic
kines, and other factors through NF-kB, ERK, and STAT3 sign
family member NLRP12 plays a critical role in downregulating
tance of anti-inflammatory signals inmaintaining colonic home
ling inflammation and tumorigenesis in the gut, and may help i
bowel diseases.
Canmation in IBD patients contribute to mutagenic transformation
of colonic epithelial cells into neoplastic cells (Grivennikov
et al., 2010).
Chronic inflammatory diseases of the gut are initiated by the
aberrant interaction of the host immune system with commensal
microflora (Goyette et al., 2007; Zaki et al., 2011). Innate immune
receptors such as Toll-like receptors (TLR) at the surface of
epithelial cells and immune cells initiate this inflammatory
process by activating the downstream transcription factor
NF-kB, which is a central mediator of proinflammatory cytokine
and chemokine production. However, a tight regulation of NF-kB
signaling is essential to maintaining a beneficial level of homeo-
static interactions with the gut microflora. Therefore, deregu-
lated NF-kB signaling may represent a key mechanism contrib-
uting to gut inflammation, colitis, and colorectal tumorigenesis
(Leu et al., 2003; van Vliet et al., 2005; Yu et al., 2009). Recentthe second leading cause of cancer-related death in devel-
micro-environment in the gut by inducing cytokines, chemo-
aling. In this study, we showed that the NOD-like receptor
these tumor-inducing signaling pathways. Given the impor-
ostasis, these results reveal a regulatorymechanism control-
dentify new therapeutic approaches to control inflammatory
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regulate NF-kB activation in maintenance of gut homeostasis.
For instance, enterocyte-specific deletion of the NF-kB regulator
A20 rendered mice hypersusceptible to colitis and colorectal
tumorigenesis as a consequence of uncontrolled production of
NF-kB-dependent proinflammatory cytokines (Lee et al., 2000;
Vereecke et al., 2010). Similarly, mice deficient in TIR8/SIGGIR,
a molecule that negatively regulates Toll-like receptor (TLR)-
and interleukin (IL)-1 receptor-mediated NF-kB signaling,
suffered from increased susceptibility to colitis and colorectal
tumorigenesis (Garlanda et al., 2004; Xiao et al., 2010).
In addition to TLRs, the immune systemmakes use of a limited
set of germ-line encoded pattern recognition receptors (PRRs) to
induce the production of inflammatory cytokines in response to
microbial components (Kawai and Akira, 2007). This includes
C-type lectin receptors (CLRs), RIG-I-like receptors (RLRs),
HIN-200 proteins and nucleotide binding, and oligomerization
domain-like receptors (NLRs) (Inohara et al., 2005; Kanneganti
et al., 2006, 2007). NLR proteins represent platform proteins
that are characterized by the presence of a conserved nucleotide
binding and oligomerization domain (referred to as NBD; NOD or
NACHT domain) and are located in intracellular compartments
(Kanneganti et al., 2007). NLRs are implicated in a multitude of
innate immune signaling pathways ranging from the regulation
of MAP kinase and NF-kB signaling pathways by NOD1 and
NOD2, over modulation of MHC class II genes by CIITA, to the
assembly of caspase-1-activating protein complexes named
‘‘inflammasomes’’ by the NLR proteins NLRP1, NLRP3, and
NLRC4 (Kanneganti et al., 2007). Unlike the above-mentioned
NLRs, the in vivo role of the NLR protein NLRP12 is not clear.
Notably, polymorphisms in the gene encoding NLRP12 have
been linked with increased susceptibility to periodic fever
syndromes and atopic dermatitis (Arthur et al., 2010; Borghini
et al., 2011; Je´ru et al., 2008; Macaluso et al., 2007). NLRP12
was initially shown to regulate NF-kB and caspase-1 activation
(Wang et al., 2002). Moreover, NLRP12 was recently suggested
to negatively regulate canonical and noncanonical NF-kB sig-
naling in vitro by targeting the kinases IRAK1 and NIK for protea-
somal degradation (Arthur et al., 2007; Lich et al., 2007; Williams
et al., 2005). However, NLRP12 missense mutations in periodic
fever syndrome patients were recently linked to increased cas-
pase-1 activation rather than to inhibition ofNF-kBsignaling (Bor-
ghini et al., 2011; Je´ru et al., 2010). Therefore, the physiological
relevance of NLRP12-mediated regulation of NF-kB pathways
remains to be defined. In this study we focused on determining
the physiological role of NLRP12 in regulating inflammation in
a mouse model of colitis and colorectal tumorigenesis.
RESULTS
Generation of Nlrp12-Deficient Mice
Mouse NLRP12 shares with other NLRs a structural composition
that exists of an amino-terminal Pyrin motif, followed by a central
nucleotide-binding domain (NBD) and a C-terminal leucine rich
repeat domain (see Figure S1A available online). The product is
encoded onmouse chromosome 7 and contains 10 exons span-
ning a region of 28.3 kb. We initially investigated the expression
pattern of murine Nlrp12 transcripts in a variety of primary
immune cell populations. Cells with the highest expression650 Cancer Cell 20, 649–660, November 15, 2011 ª2011 Elsevier Inclevels of Nlrp12 mRNA were neutrophils and T cells, followed
by dendritic cells and macrophages, respectively (Figure 1A).
Recently, it was reported that NLRP12 is expressed in the colon
tissue (Lech et al., 2010). We further verified the expression of
Nlrp12 in different parts of the gastrointestinal tract and lymphoid
organs. Nlrp12 was found to be expressed in the small intestine,
caecum, colon, spleen, liver, andmesenteric lymph nodes (MLN)
(Figure 1B). To define the role of NLRP12 in regulating inflamma-
tory responses in the gut, Nlrp12-deficient mice were generated
by homologous recombination. To this aim, exon II encoding the
Pyrin domain of Nlrp12—that is required for the recruitment of
downstream effectors and functions of the protein—was re-
placed with a neomycin selection cassette in the targeting
construct (Figures S1B and S1C). Positive embryonic stem
(ES) cells were used to generate chimeric mice and Nlrp12/
mice were backcrossed to the C57BL/6 genetic background
for 10 generations. Nlrp12/ mice were fertile and appeared
healthy when housed in a specific pathogen-free environment.
Nlrp12-Deficient Mice Are Hypersusceptible
to DSS-Induced Colitis
To define the role of NLRP12 in colitis-induced inflammation,
Nlrp12/ mice were fed 3% DSS in drinking water for 5 days
and susceptibility was monitored by measuring body weight,
assessing stool consistency and rectal bleeding, and measur-
ing colon length during both the acute (day 5) and recovery
(days 9–20) stages of disease. Notably, disease progression
and clinical scores of wild-type and Nlrp12-deficient mice were
not statistically different during the acute phase of disease. How-
ever, wild-type mice started to recover once DSS was omitted
from the drinking water, whereas Nlrp12-deficient mice suffered
from continued body weight loss (Figure 1C), diarrhea, and rectal
bleeding (Figure 1D). This inflammatory phenotype was further
evidenced by the gross appearance of the colon. During the
acute stage of colitis (at day 5), colons of wild-type and
Nlrp12-deficient mice appeared similar (data not shown). At
day 9, however, colons of Nlrp12-deficient mice were signifi-
cantly shorter than those of wild-type mice (Figures 1E and
1F). To determine whether recovery in Nlrp12/ mice was
simply delayed, or whether NLRP12-deficiency prevented heal-
ing responses at later time points as well, colon length, and
weight of Nlrp12/ mice were analyzed at day 20 after DSS-
induced colitis. Notably, colons of Nlrp12/ mice were signifi-
cantly shorter and weighted more than those of wild-type
mice (Figures S1D and S1E), suggesting that Nlrp12/ mice
continued to suffer from colon inflammation 2 weeks after DSS
administration was stopped. Consistent with an inflammatory
phenotype, MLN and spleens of DSS-fed Nlrp12/ mice were
found to be significantly heavier and enlarged at day 20
compared to those of wild-type mice (Figures S1F and S1G).
To obtain further evidence of sustained inflammation inNlrp12-
deficientmice, colon tissuewas analyzed histologically at days 5,
9, and 20 following DSS administration. Consistent with the
clinical parameters discussed above, colons of Nlrp12-deficient
mice contained markedly more infiltrating inflammatory cells,
and displayed significantly more ulceration and hyperplasia
during the recovery phase of the disease (at days 9 and 20),
but not at early stages (Figures 1G and 1H). In agreement, colon
tissue of Nlrp12-deficient mice contained significantly higher.
Figure 1. Nlrp12-Deficient Mice Are Hypersuscep-
tible to DSS-Induced Colitis
(A) Real time PCR analysis for mRNA of Nlrp12 in macro-
phages, dendritic cells (DC), PMN and T cells collected
from wild-type mouse.
(B) Real time PCR analysis for mRNA of Nlrp12 in liver,
spleen, small intestine (SI), cecum, colon and MLN. (C, H)
Wild-type and Nlrp12/ mice were fed a 3% DSS-solu-
tion in drinking water for 6 days followed by regular
drinking water until the end of the study.
(C and D) Body weight (C) and clinical score (D; stool
consistency plus rectal bleeding score) were scored daily.
Data represent means ± SEM; n = 20/group; *p < 0.05;
**p < 0.01.
(E and F) Mice were sacrificed on day 5 and 9 to measure
colon length. Histopathological changes in colon tissue
collected at day 5, 9, and 20 were examined by H&E
staining.
(G) Semiquantitative scoring of histopathology.
(H) Representative images of H&E staining of colon
section at day 0, 5, 9, and 20 after DSS administration.
Scale bar represents 50 mM. Data represent means ±
SEM. *p < 0.05; **p < 0.01. See also Figure S1.
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day 9 (Figure S1H), but not at day 5 post-DSS administration
(data not shown). Together, these results indicate that NLRP12
plays a critical role in resolving the inflammatory response
following DSS-induced injury of the colonic epithelium.
NLRP12 Suppresses Colitis-Associated Tumorigenesis
The observation that Nlrp12-deficient mice suffered from sus-
tained gut inflammation upon DSS-treatment, prompted us to
investigate the role ofNlrp12 in colitis-associated tumorigenesis.
To this aim, we induced colon tumorigenesis by injecting a
single dose of the DNA-methylating agent azoxymethane
(AOM), which was followed by three cycles of 3% DSS-adminis-
tration (Figure 2A). Changes in body weight weremonitored daily
throughout the study duration and colonic tumor burden was
determined 12 weeks after AOM/DSS treatment. Nlrp12-defi-
cient mice lost significantly more body weight relative to wild-
type mice (Figure 2B) and showed increased rectal bleeding
(Figure S2A). Consistently, Nlrp12-deficient mice had signifi-Cancer Cell 20, 649–cantly higher tumor burdens in the colon,
although tumor size was not significantly
different (Figures 2C–2E). Tumors in wild-type
mice were mostly contained within the colo-
rectal and distal areas of the colon, whereas
tumors inNlrp12-deficient micewere commonly
found throughout the entire colonic tract
(Figures S2B and S2C). Increased tumor
burdens in Nlrp12-deficient mice were associ-
ated with more inflammation and hyperplasia
(Figures 2F and 2G), and a higher incidence of
dysplasia (Figure 2H). Histological examination
of tumors and adenomatous polyps showed
that all Nlrp12-deficient mice included in the
study developed high-grade dysplasia, of which
30% were classified as adenocarcinoma
(Figures 2H and 2I). By contrast, only 20% ofthe wild-type cohort displayed high-grade dysplasia in the colon,
and adenocarcinoma development was not evident in this group
(Figure 2I). Collectively, these results indicate a critical role for
NLRP12 in protection against colitis-associated tumorigenesis.
NLRP12 Dampens Inflammatory Responses
after Colitis Induction
The splenomegaly of DSS-fed Nlrp12-deficient mice (Fig-
ure S1G) was also apparent in AOM/DSS-administered animals
(Figures S3A and S3B). We therefore hypothesized that NLRP12
may protect from colitis-associated tumorigenesis by damp-
ening immune cell activation and inflammatory responses in
response to DSS-treatment. To characterize this possibility in
additional detail, we carefully examined the histopathological
changes that occur during early stages of tumor induction
(at day 15 after AOM injection). In line with our hypothesis, histo-
logical analysis of colon sections revealed markedly more tissue
damage, mucosal edema, inflammation, and hyperplasia in
Nlrp12-deficient mice than in wild-type mice (Figures 3A and660, November 15, 2011 ª2011 Elsevier Inc. 651
Figure 2. Increased Colitis-Associated Colorectal
Tumorigenesis in Nlrp12-Deficient Mice
(A) WT (n = 16),Nlrp12/ (n = 14), were injected with AOM
on day 0 (d0), and were then given a 3% DSS solution
during three 5-day cycles as described in Experimental
Procedures.
(B) Body weight changes were monitored throughout the
study.
(C) Twelve weeks after AOM injection, mice were sacri-
ficed to determine tumor development in the colon.
(D and E) Number of tumors in the whole colon was
counted (D), and diameter of the tumors (E) was measured
at the end of the study. At the same time colons were
processed for histopathological analysis.
(F and G) H&E stained sections were scored for inflam-
mation, ulceration, hyperplasia, and inflamed area.
(H) Overall grading of dysplasia in each genotype.
(I) Representative high magnification images showing
dysplasia in colon tissue. Scale bar represents 100 mM.
Data represent means ± SEM; *p < 0.05, **p < 0.01. See
also Figure S2.
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and hyperplasia were all significantly higher in Nlrp12-deficient
mice (Figure S3C). Moreover, Nlrp12-deficient colons showed
increased infiltration of macrophages, PMNs, and T cells (Fig-
ure 3C). Hyperinfiltration of immune cells in Nlrp12/ mice
was not confined to inflamed sections of the colon, but extended
to the entire colon as evidenced by an increased F4/80-
staining in relatively noninflamed parts of the Nlrp12/ colon
(Figure 3D).
To further characterize the immune cell types associated with
the induction of hyperinflammatory responses in the colon of
Nlrp12/mice,myeloid cells present in the colonic lamina prop-
ria were isolated at different stages of colitis and analyzed by
flow cytometry. During early stages of colitis (at day 5), neutro-
phils were the most prevalent cell type found in the lamina prop-
ria of both wild-type and Nlrp12/ mice, but their number was
nearly doubled in Nlrp12-deficient colons (Figure 3E). Notably,
at later stages of colitis (days 9 and 20), cell counts of all analyzed
myeloid cell types (CD11b+, F4/80+, CD11c+, Gr-1+) inNlrp12/
mouse colons were significantly higher than in wild-type colons
(Figures 3F and 3G). At day 20, a similarly dramatic increase in
infiltration of myeloid cell populations was evident in the mesen-652 Cancer Cell 20, 649–660, November 15, 2011 ª2011 Elsevier Inc.teric lymph node (MLN) and spleen of Nlrp12/
mice, although myeloid cell counts in these
tissues were comparable to those of wild-type
mice at earlier time points (Figure 3G; Fig-
ure S3D). Notably, number and frequency of
myeloid cell populations in untreated control
mice of wild-type and Nlrp12/ background
were not different (data not shown). In addition
to being more prevalent, a larger number of
CD11b+ myeloid cells that were collected from
the spleen and MLN of Nlrp12/ mice at
day 20 produced IL-6 and TNF-a in response
to LPS and following PMA plus ionomycin
stimulation (Figure 4A). Moreover, the mean
fluorescent intensity (MFI) for intracellular
expression for IL-6 and TNF-a was significantlyhigher for Nlrp12-deficient CD11b+ cells than for wild-type cells,
indicating that Nlrp12/myeloid cells produced higher levels of
these proinflammatory cytokines (Figure 4B). Thus, together
these results indicate that NLRP12 plays a critical role in damp-
ening the inflammatory response in myeloid cells and during
DSS-induced colitis.
Enhanced Cytokine and Chemokine Production
in Nlrp12-Deficient Mice Drives Hyperplasia
and Tumorigenesis
Consistent with the enhanced infiltration and hyperactivation of
myeloid cells in the absence of NLRP12, the production of
proinflammatory cytokines such as IL-1b, IL-6, TNF-a, IL-17,
and IL-15 were all found to be elevated in the colon of Nlrp12/
mice relative to the levels found in wild-type mice (Figure 4C
and data not shown). Similarly, colons of Nlrp12-deficient
mice contained higher levels of the chemokines G-CSF,
eotaxin, KC, IP-10, MIP-1a, MIP-1b, and MIP2 (Figure 4C and
data not shown). Given the association of higher tumor burdens
with enhanced production of proinflammatory cytokines and
chemokines in Nlrp12/ mice, we hypothesized that unlike
most NLRs, NLRP12 may operate as a negative regulator of
Figure 3. Nlrp12-Deficiency Leads to Increased
and Prolonged Inflammatory Responses in Colon
Tissue
Wild-type andNlrp12/micewere injectedwith AOMand
5 days later mice were fed with 3% DSS in drinking water
for 5 days. Distal colons were collected at day 15 after
AOM injection and examined after H&E staining.
(A) Representative images of H&E stained sections of
distal colon. Scale bar represents 200 mM.
(B) Total histological scores of whole colon at the same
time. Data represent means ± SEM; n = 5/group; *p < 0.05.
(C) Colon tissue was immunostained for the macrophage
marker F4/80, PMN marker Gr-1, and T cell marker CD3.
Scale bar represents 100 mM.
(D) F4/80 staining in noninflamed part of the colon at day
10 after DSS. Scale bar represents 20 mM.
(E–G) In a separate experiment, mice were fed with 3%
DSS for 5 days followed by normal drinking water until day
20. Colon, MLN, and spleenwere collected at day 5, 9, and
20 after DSS. Colonic lamina propria cells, MLN cells, and
splenocytes were analyzed flow cytometrically after
staining for myeloid cell markers CD11b, F4/80, CD11c,
and Gr-1. Total number of CD11b+, F4/80+, CD11c+, and
Gr-1+ cells at day 5 (E), day 9 (F), and day 20 (G). Data
represent means ± SEM; n = 5/group; *p < 0.05; **p < 0.01.
See also Figure S3.
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explain its antitumor function because increased cytokine and
chemokine production, along with tumorigenic growth factors,
may create a microenvironment that promotes unwarranted
cell proliferation and adenomatous polyp development in
Nlrp12/ mice.
To understand the nature of the tumorigenic signals that are
deregulated in Nlrp12/mice, we first studied apoptosis induc-
tion in colon tissue of AOM/DSS-treated mice. However, mRNA
and protein expression of the antiapoptotic protein Bcl-XL as
well as the number of TUNEL-positive cells in colon tissue of
wild-type and Nlrp12/ mice were comparable (Figure S4).
We next analyzed the expression of multiple cytokines and
tumorigenic factors such as cycloxygenase 2 (COX2) and induc-
ible nitric oxide synthase (iNOS /NOS2) in colon tissue because
these factors often drive tumorigenesis. The transcript level of
proinflammatory cytokines such as IL-6 and TNF-a and the che-
mokine MIP2 were markedly more induced in Nlrp12/ mice
relative to the levels in wild-type colon (Figure 5A). Unlike IL-6Cancer Cell 20, 649–and TNF-a, the levels of the tumor-suppressing
cytokine IFN-g and its effector IFN-g-depen-
dent NOS2 transcripts were not significantly
changed (Figure 5A). In contrast, we measured
3-fold higher mRNA levels of the prosta-
glandin-synthesizing enzyme COX2, which has
previously been linked to colon carcinogenesis
(Buchanan and DuBois, 2006; Shiff and Rigas,
1999). Moreover, elevated COX2 and MIP2
expression was also evident in colonic tumors
of Nlrp12-deficient mice (Figure 5B).
The expression of tumorigenic and proinflam-
matory genes is modulated by signal transduc-
tion pathways mediated by NF-kB, MAPK,STAT, and AKT proteins. To understand whether these path-
ways and molecules were deregulated in the absence of
Nlrp12, we examined activation of NF-kB, MAPK, and STAT
signaling pathways by western blotting. Indeed, significantly
higher activation levels of NF-kB, ERK, and STAT3 were
observed in Nlrp12-deficient colon tissue at day 15 after AOM
injection (day 10 after DSS) relative to the levels found in wild-
type mice (Figures 5C and 5D). Hyperactivation of these
inflammatory pathways is associated with an increased prolifer-
ation of epithelial cells in hyperplastic colon regions of AOM/
DSS treated Nlrp12-deficient mice (Figures 5E and 5F). By
contrast, untransformed colon tissue and unaffected colon
regions of both Nlrp12/ and wild-type mice displayed similar
proliferation levels as measured by BrdU staining (data not
shown). Notably, hyperplastic colonic tissue in Nlrp12-deficient
mice was surrounded by a massive infiltration of macrophages
(Figure 5G), suggesting that myeloid cells may provide signals
that promote tumorigenesis in the absence of NLRP12
signaling.660, November 15, 2011 ª2011 Elsevier Inc. 653
Figure 4. Nlrp12-Deficiency Leads to Enhanced
Cytokine Production
WT and Nlrp12/ mice were fed with 3% DSS for 5 days
followed by normal drinking water until day 20. MLN and
spleen were collected at day 20 after DSS administration
and cells were stimulated with either LPS (1 mg/ml) or PMA
(25 ng/ml) plus ionomycin (500 ng/ml) for 5 hr. After stim-
ulation cells were stained for myeloid cell marker CD11b,
and intracellular cytokines IL-6 and TNFa.
(A) Frequency of CD11b+TNFa+ and CD11b+IL-6+ cells.
(B) Mean fluorescent intensity (MFI) of IL-6+CD11b+ and
TNFa + CD11b+ cells in LPS stimulated MLN and spleen.
Data represent means ± SEM; n = 5/group; *p < 0.05, **p <
0.01. In a separate experiment, wild-type and Nlrp12/
mice were injected with AOM and 5 days later mice were
fed with 3% DSS in drinking water for 5 days.
(C) Whole colons were collected at day 14 and day 18 after
AOM injection and homogenates were used to determine
cytokines by multiplex ELISA. Data represent means ±
SEM; n = 7–8/group; *p < 0.05, **p < 0.01.
Cancer Cell
NLRP12 Dampens Inflammation and TumorigenesisNLRP12 Signaling in the Hematopoietic Compartment
Is Critical for Protection against Colitis
and Colitis-Associated Tumorigenesis
To determine the cell populations that contribute to NLRP12-
mediated protection against tumorigenesis, we generated 4
groups of Nlrp12 bone marrow chimeras (Figure 6A). Eight
weeks after bone marrow reconstitution, mice were subjected
to tumor induction using AOM plus DSS. NLRP12 deficiency in
either compartment led to increased bodyweight loss compared
to wild-type mice (Figure 6A), suggesting that NLRP12 may
contribute to protection against colitis in both immune and non-
immune cells. However, the body weight of Nlrp12-deficient
mice with wild-type hematopoietic cells later recovered to level
similar to those of wild-type mice, whereas mice lacking
NLRP12 in the hematopoietic compartment failed to do so (Fig-
ure 6A). This suggests that NLRP12 signaling in immune cells is
critical to controlling colitis, whereas its role in epithelial cells
may be redundant. Consistently, the groups lacking Nlrp12 in
the hematopoietic compartment had significantly higher tumor
burdens and shortened colons (Figures 6B and 6C). On the other
hand, no significant differences in tumor burdens and colon
length were observed between wild-type and Nlrp12-deficient
mice having wild-type bone marrow cells (Figures 6B and 6C).
In agreement, colon tissue of chimera groups with Nlrp12-defi-654 Cancer Cell 20, 649–660, November 15, 2011 ª2011 Elsevier Inc.cient immune cells that was collected at day
15 after AOM injection (day 10 after DSS)
showed increased NF-kB and ERK activation
(Figures 6D and 6E). Together, these results
suggest that Nlrp12-deficient myeloid cells,
particularly macrophages, fail to silence NF-kB
and ERK signaling pathways, which ultimately
results in elevated cytokine levels, inflammatory
responses, and colon tumorigenesis during
colitis.
NLRP12 Negatively Regulates NF-kB
and ERK Signaling in Macrophages
To gather further evidence for deregulated
NF-kB and ERK signaling in Nlrp12-deficientmacrophages, bone marrow-derived macrophages from wild-
type and Nlrp12-deficient mice were stimulated with LPS,
and activation of NF-kB, MAPK, and STAT3 was analyzed by
western blotting at different time points. In agreement with
the notion that NF-kB activation is enhanced in Nlrp12-deficient
cells, both IkBa degradation and phosphorylation were found
to be increased over a range of time points covering 10 min
and up to 2 hr after LPS exposure (Figures 7A and 7B). Further-
more, enhanced phosphorylation of ERK was apparent in
LPS-stimulated Nlrp12-deficient macrophages (Figure 7A). In
contrast, activation levels of STAT3 and the MAP kinases
p38 and JNK were comparable to those of wild-type macro-
phages (Figure 7A and data not shown), confirming the
specificity of these results. Enhanced NF-kB and ERK activa-
tion in Nlrp12-deficient macrophages was not due to deregu-
lated inflammasome activity, because caspase-1 activation in
response to the inflammasome activators LPS plus ATP, and
upon infection with Salmonella or Listeria was not affected
(Figure S5A).
We next addressed the question whether the increased acti-
vation of NF-kB and ERK in Nlrp12-deficient macrophages is
confined to the TLR4 ligand LPS, or a general response seen
with other TLR ligands as well. Wild-type and Nlrp12/ macro-
phages stimulated with the TLR2 ligand Pam3-CSK4 and the
Figure 5. Enhanced Proinflammatory Cytokine
Levels in Colon Tissue of Nlrp12-Deficient Mice
Augments Production of Tumor-Inducing Factors
Wild-type andNlrp12/micewere injectedwith AOMand
5 days later mice were fed with 3% DSS in drinking water
for 5 days.
(A) Distal colons collected at day 15 after AOM injection
were used to isolate RNA for expression analysis of IL-6,
TNF-a, IFN-g, MIP2, COX2, and NOS2 by real time PCR.
Data represent means ± SEM; n = 5–7/group; *p < 0.05,
**p < 0.01.
(B) Real time PCR analysis for COX2 and MIP2 in distal
colon tumors collected at 12 weeks after AOM/DSS
treatment. Data represent means ± SEM; n = 5–7/group;
**p < 0.01.
(C) Whole colon tissue homogenates collected at 15 days
after AOM injection (10 days after DSS) were examined for
activation of NF-kB, p38, ERK, and STAT3 by western blot
analysis. Each lane corresponds individual mouse.
(D) Densitometric analysis of p-IkBa, p-ERK, and p-STAT3
relative to their total protein. Data represent means ± SD;
n = 5/group; *p < 0.05. In a separate experiment, mice
were injected intraperitoneally with BrdU either at day 15
or 12 weeks after AOM injection. Colon sections were
stained for BrdU-positive cells and macrophages.
(E) Representative images of BrdU staining at 15 days and
12 weeks after tumor induction. Scale bar represents
50 mM.
(F) Number of BrDU-positive cells at day 10 after DSS
treatment (day 15 after AOM). Data represent means ±
SEM; n = 4 mice/group; 3 different section per mouse;
50 field per section; *p < 0.05.
(G) Serial sections of Nlrp12/ mouse colon at day 10
(day 15 after AOM) were stained for macrophage marker
F4/80 (lower panel) and BrdU-positive cells (upper panel).
Scale bar represents 20 mM. See also Figure S4.
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induced enhanced NF-kB and ERK activation inNlrp12-deficient
macrophages (Figures 7C–7F), indicating a role for NLRP12 in
negatively regulating NF-kB and ERK signaling downstream of
multiple TLRs. In agreement with the in vivo data presented
earlier, expression of IL-6, KC, TNF-a, COX2 and MIP2 were
all significantly increased in LPS-stimulated Nlrp12-deficient
macrophages at the mRNA (Figure 7G) and protein levels
(Figure S5B).
Previous studies suggested NLRP12 to suppress canonical
NF-kB activation by preventing IRAK1 phosphorylation, and to
downregulate noncanonical NF-kB signaling by inducing pro-
teosomal degradation of NIK (Lich et al., 2007; Williams et al.,
2005). To determine whether the canonical and/or noncanonical
NF-kB signaling was altered in Nlrp12-deficient macrophages
upon LPS stimulation, we analyzed the phosphorylation status
of the noncanonical effector P100, and that of P105 for canon-
ical NF-kB signaling. Interestingly, the levels of phosphorylated
P105 were markedly induced in Nlrp12-deficient macrophages
after LPS-stimulation (Figure 8A). In contrast, the levels of phos-
phorylated P100 appeared comparable in LPS-stimulated wild-
type and Nlrp12/ macrophages (Figure 8A). To understand
whether NLRP12 suppresses canonical NF-kB pathway duringCanLPS stimulation, we performed western blot analysis of phos-
pho-P105 and phospho-P100 in cytosolic lysate and RelA
(p65) and RelB in nuclear lysate of macrophages. As shown in
Figure 8B, phosphorylated P105 levels were markedly higher
in Nlrp12/ macrophages than in wild-type cells. Moreover,
increased amounts of RelA were detected in the nucleus of
Nlrp12-deficient macrophages that had been stimulated with
LPS (Figure 8C). Finally, we measured the DNA-binding activity
of p65 in nuclear isolates of LPS-stimulated macrophages. A
significantly higher p65 DNA-binding activity was measured in
nuclear lysates of LPS-stimulated Nlrp12-deficient macro-
phages (Figure 8D). Although our results do not exclude the
possibility of NLRP12 regulating noncanonical NF-kB signaling
in response to TNF-a receptor family ligands such as CD40L
(Lich et al., 2007), it confirms that NLRP12 potently downregu-
lates TLR-induced activation of canonical NF-kB signaling,
as previously suggested (Je´ru et al., 2010). In conclusion,
NLRP12 dampens inflammation and colon tumorigenesis by
attenuating activation of NF-kB and ERK signaling in myeloid
cells. In the absence of NLRP12, upregulated production of
inflammatory cytokines and tumorigenic factors drives the
transformation of epithelial cells and supports colitis-associated
tumorigenesis.cer Cell 20, 649–660, November 15, 2011 ª2011 Elsevier Inc. 655
Figure 6. NLRP12 Signaling in Hematopoietic
Cells Is Critical for Protection Against Colon
Tumorigenesis
Bone marrow chimera mice for Nlrp12 were generated as
described in Experimental Procedures. Eight weeks after,
mice (8–10/group) were induced tumorigenesis using
AOM/DSS regimen as described in Experimental Proce-
dures.
(A) Body weight was monitored every alternate day.
(B and C) Tumor burden in whole colon and length of colon
were measured at 12 weeks after tumor induction. Data
represent means ± SEM; *p < 0.05.
(D) In a separate study, colon tissue collected at 15 days
after AOM injection were processed for western blot
analysis for IkB, p-IkB, ERK, and p-ERK.
(E) Densitometric analysis of p-IkBa and p-ERK relative
to their total protein. Data represent means ± SD;
n = 3/group; *p < 0.05; **p < 0.01.
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Our studies demonstrate that NLRP12 plays an essential role in
the suppression of proinflammatory cytokines and chemokines
by controlling the activation of NF-kB and ERK pathways in
response to microbial components and in colitis and colorectal
tumorigenesis. Colorectal tumorigenesis is a leading cause of
cancer-related death. IBD is a predisposing factor of colorectal
cancer (Itzkowitz and Yio, 2004). Chronic colitis develops due
to hyperactivation of immune cells upon permeabilization of the
colonic epithelial barrier in genetically susceptible hosts (Hill
andArtis, 2010). Inflammatory processes initiatedupondetection
of commensal flora by NLRs and other PRRs primarily aim to
control the infection and to restore the damage to the epithelial656 Cancer Cell 20, 649–660, November 15, 2011 ª2011 Elsevier Inc.layer (Medzhitov, 2007). However, a tight regula-
tion of inflammatory signaling pathways is
critical to maintain immune responses at
homeostatic levels. Excessive inflammation is
destructive by itself and activates cells of the
adaptive immune system, which may ultimately
result in the development of autoimmunity
(Liew et al., 2005). Therefore, the mechanisms
controlling inhibition of NF-kB and other
inflammatory signaling pathways are equally
important as those driving inflammation.
Indeed, deletion of negative regulators of NF-
kB such as A20, TIR8, andDUBAwas previously
shown to lead to increased susceptibility to
DSS-induced colitis (Garlanda et al., 2004;
Gonza´lez-Navajas et al., 2010; Lee et al., 2000;
Vereeckeet al., 2010; Xiaoet al., 2010). Similarly,
we showed here that Nlrp12 deficiency leads to
increased susceptibility to colitis and colitis-
associated tumorigenesis in mice by a failure
to dampen inflammatory signaling pathways.
In this study we propose that NLRP12 activity
in macrophages plays a major role in attenu-
ating colon inflammation and tumorigenesis in
mice. Our interpretation is based on several
evidences. At first, we demonstrated thatNLRP12 activity in the mouse myeloid compartment is critical
in protection against colitis-associated colon tumorigenesis.
Second, Nlrp12-deficient macrophages are hyperresponsive to
TLR ligands, showing increased activation of NF-kB and ERK.
Increased macrophage density in tumor tissue is strongly linked
with poor prognosis of human cancer (Chen et al., 2005). A
growing body of evidence suggests that activated macrophages
in human colorectal tumors produce tumor promoting cytokines
such as IL-6 and TNF-a, chemokines KC and MIP2, enzymes
matrix metalloproteinases, COX2 and NOS2, and growth factors
(Qian and Pollard, 2010). Notably, NLRP12 is expressed in both
human and mouse monocytic cells (Lich et al., 2007; Williams
et al., 2005). It was shown that human monocytic cells having
mutation in NLRP12 are hyperinflammatory in nature and linked
Figure 7. NLRP12 Negatively Regulate NF-kB and
ERK Activation in Macrophages
(A–F) Bone marrow-derived macrophages were cultured
as described in Experimental Procedures and were stim-
ulated with (A) LPS (1 mg/mL), (C) Pam3-CSK4 (5 mg/mL)
(E) poly(I:C) (1 mg/mL). Cell lysates collected at indicated
time points were analyzed for p-IkB, I-kB, p-P38, p-ERK,
ERK, p-JNK, and JNK by western blotting. Densitometric
analysis of band intensity of p-IkBa and p-ERK relative to
IkBa and ERK of LPS- (B), Pam3CSK4- (D), and Poly(I:C)-
treated (F) cells.
(G) LPS-stimulated wild-type and Nlrp12-deficient
macrophages were collected at different time points and
mRNAwas isolated for real-time quantitative PCR analysis
of IL-6, KC, TNF-a, MIP2, COX2, and NOS2 synthesis.
Data represent means ± SD of triplicate wells; *p < 0.05;
**p < 0.01. See also Figure S5.
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2008). Mutations in other NLR genes such as NOD2 and
NLRP3were previously shown to be associated with autoinflam-
matory diseases and IBD (Hugot et al., 2001; Maeda et al., 2005;
Miceli-Richard et al., 2001; Ogura et al., 2001; Schoultz et al.,
2009; Villani et al., 2009; Zaki et al., 2010). Therefore, hyperin-
flammatory nature of Nlrp12-deficient macrophages as seen in
this study of mouse model of colorectal tumorigenesis suggests
a critical role of NLRP12 in the protection of human colon
inflammation and colorectal cancer.
Several tumorigenic factors produced by tumor-associated
macrophages are regulated by the signaling pathways NF-kB,
STAT3 and ERK. The critical role of NF-kB in bothmousemodels
and human colorectal tumorigenesis is well-known (Greten et al.,
2004; Luo et al., 2004; Terzic et al., 2010). Recent studies in a
mouse model of colorectal tumorigenesis demonstrated that
both ERK and STAT3 activation are an integral part of tumor
development (Bollrath et al., 2009; Kujawski et al., 2008; Lee
et al., 2010). ERK regulates several tumorigenic factors suchCancer Cell 20, 649–as COX2, by activating the oncogenic tran-
scription factor cMyc (Wilkins and Sansom,
2008). STAT3 regulates the proinflammatory
cytokines IL-17 and IL-23, the antiapoptotic
protein Bcl-xL and several growth factors (Yu
et al., 2009). Therefore, higher activation of NF-
kB, ERK and STAT3 in Nlrp12-deficient colon
tissue during the recovery stage of the disease
strongly supports our phenotypic observation
as well as explains the mechanism of increased
tumor incidence in Nlrp12-deficient mice.
In summary, our study provides evidence for
an anti-inflammatory and antitumorigenic role
for NLRP12 in vivo by negatively regulating
NF-kB and ERK signaling. Considering the
importance of anti-inflammatory signals in
maintaining colonic homeostasis, our study on
the anti-inflammatory function of NLRP12 in
colitis and colon tumorigenesis bears enormous
importance. This study demonstrates a regula-
tory mechanism of intestinal inflammation and
tumorigenesis by PRRs and paves the way tofurther understanding the role of NLR proteins in gastrointestinal
disorders. This may help identify new therapeutic approaches to
control this increasingly important health problem.
EXPERIMENTAL PROCEDURES
Mice
Nlrp12 knock-out mice were generated by homologous recombination in ES
cells by replacement of exon II of the Nlrp12 gene encoding the N-terminal
Pyrin domain with an IRES-b-gal-neomycin-resistance cassette via a targeting
vector (Figure S1B). A positive ES clone was used to generate chimeric mice.
129/C57BL/6 chimeric mice were crossed with C57BL/6 females to generate
heterozygous mice. Nlrp12/ mice were further backcrossed to C57BL/6
background for 10 generations. Male mice 8–10 weeks of age maintained in
a pathogen-free facility were used in this study. Animal studies were conduct-
ed under protocols approved by St. Jude Children’s Research Hospital
Committee on Use and Care of Animals.
Induction of DSS-Induced Colitis
Acute colitis was induced with 3% (w/v) DSS (molecular mass 36–40 kDa;
MP Biologicals) dissolved in sterile, distilled water ad lib for the experimental660, November 15, 2011 ª2011 Elsevier Inc. 657
Figure 8. NLRP12 Is a Negative Regulator of
Canonical NF-kB Signaling Pathway in Response
to LPS
(A and B) Bone marrow-derived macrophages from
wild-type and Nlrp12/ mice were stimulated with LPS
(1 mg/mL). Total cell lysate (A) and cytoplasmic fraction (B)
were analyzed for phosphorylation of P100 and P105 by
western blotting.
(C) Western blot analysis of NF-kB complex component
RelA and RelB in nuclear fraction.
(D) 5 mg nuclear protein was assayed for p65 DNA binding
activity using commercial ELISA kit as described in
Experimental Procedures. Absorbance at 450 nm repre-
sents corresponding DNA binding activity of P65 (RelA)
in the nuclear extract. Data represent means ± SD
of triplicate wells in ELISA assay of a single sample;
**p < 0.01.
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The DSS solutions were made fresh on day 3.
Clinical Scoring of Colitis
Scoring for stool consistency and occult blood was done as previously
described (Zaki et al., 2010). Briefly, stool scores were determined as follows:
0 = well-formed pellets, 1 = semiformed stools that did not adhere to the anus,
2 = semiformed stools that adhered to the anus, 3 = liquid stools that adhered
to the anus. Bleeding scoreswere determined as follows: 0 = no blood by using
hemoccult (BeckmanCoulter), 1 = positive hemoccult, 2 = blood traces in stool
visible, 3 = gross rectal bleeding. Stool consistency scores and bleeding
scores were added and presented as clinical score.
Induction of Colorectal Cancer
Mice were injected intraperitoneally with 10 mg/kg AOM (Sigma). After 5 days,
3% DSS was given in drinking water over 5 days followed by regular drinking
water for 2 weeks. This cycle was repeated twice and mice were sacrificed
4 weeks after the last DSS cycle.
Histopathological Analysis
Formalin-preserved colon sections were processed and embedded in paraffin
by standard techniques. Longitudinal sections of 5 mm thick were stained with
hematoxylin and eosin (H&E) and examined by a pathologist blinded to the
experimental groups. Colitis scores were assigned based on the extent and
severity of inflammation, ulceration, and hyperplasia of the mucosa. Severity
scores for inflammation were as follows: 0 = normal (within normal limits);
1 = mild (small, focal, or widely separated, limited to lamina propria); 2 =
moderate (multifocal or locally extensive, extending to submucosa); 3 = severe
(transmural inflammation with ulcers covering >20 crypts). Scores for ulcera-
tion were as follows: 0 = normal (no ulcers); 1 = mild (1–2 ulcers involving
up to a total of 20 crypts); 2 = moderate (1–4 ulcers involving a total of
20–40 crypts); 3 = severe (>4 ulcers or over 40 crypts). Mucosal hyperplasia
scores were assigned as follows: 0 = normal (within normal limits); 1 = mild
(crypts 2–3 times normal thickness, normal epithelium); 2 = moderate (crypts
2–3 times normal thickness, hyperchromatic epithelium, reduced goblet cells,
scattered arborization); 3 = severe (crypts >4 times normal thickness, marked
hyperchromasia, few to no goblet cells, high mitotic index, frequent arboriza-
tion). Scoring for extent of lesions: 0 = normal (0% involvement); 1 = mild (up to
30% involvement); 2 = moderate (30%–70% involvement); 3 = severe (over
70% involvement). For immunohistochemistry, formalin-fixed paraffin-
embedded tissues were cut into 4 mm sections and slides were stained with
antibodies against the macrophage marker F4/80, neutrophil marker Gr-1,
and T cell marker CD3.
In Situ Intestinal Proliferation Assay
The number of proliferating cells in intestinal epithelium was determined
using the immunoperoxidase staining protocol with the thymidine analog658 Cancer Cell 20, 649–660, November 15, 2011 ª2011 Elsevier Inc50-bromo-20deoxyuridine (BrdU) as described earlier (Zaki et al., 2010).
In brief, 1 mg/ml BrdU in PBS was injected intraperitoneally. Three hours later,
colon tissue was collected, fixed in 10% neutral buffered formalin, and
embedded in paraffin. Immunohistochemistry was performed using an
in situ BrdU staining kit (BD Bioscience). Tissues were counterstained with
hematoxylin.
In Vitro Signaling Assays
Bone marrow cells were cultured in L-cell-conditioned IMDMmedium supple-
mented with 10% FBS, 1% nonessential amino acid, and 1% penicillin-strep-
tomycin for 5 days to differentiate into macrophages. Bone marrow derived
macrophages were seeded in 12-well cell culture plates, cultured overnight,
and stimulated with ultrapure Escherichia coli-derived LPS (Invivogen),
Pam3CSK4 (Invivogen), or Poly (I:C) (Invivogen). For analysis of caspase-1
activation, macrophages were cultured with LPS for 3 hr and then with
5 mM ATP (Sigma) for 30 min or infected with Salmonella typhimurium or Lis-
teria monocytogenes for 4 hr.
Bone Marrow Chimeras
Bone marrow transfer was used to create Nlrp12/ chimera mice wherein
the genetic deficiency of Nlrp12 was confined to either circulating cells
(Nlrp12/ >WT chimera) or nonhematopoietic tissue (WT >Nlrp12/). Briefly
bonemarrowswere collected from femur and tibia of congenicWT (expressing
CD45.1 leukocyte antigen) or Nlrp12/ (expressing CD45.2 leukocyte
antigen) donor mice by flushing with HBSS. After several washing steps, cells
were resuspended in PBS at a concentration of 1 3 108/ml. One hundred
microliters of this cell suspension was injected retro-orbitally in irradiated
donor mice. Four chimera groups were generated: WT > WT (WT cells
expressing CD45.1 into WT expressing CD45.2); WT > Nlrp12/ (WT cells
expressing CD45.1 into Nlrp12/ expressing CD45.2); Nlrp12/ > Nlrp12/
(Nlrp12/ cells expressing CD45.2 cells into Nlrp12/ expressing CD45.2);
and Nlrp12/ > WT (Nlrp12/ cells expressing CD45.2 into WT expressing
CD45.1). The use of CD45.1-expressing congenic mice facilitated verification
of proper reconstitution in the chimera mice. Bone marrow reconstitution effi-
ciency was verified after 6 weeks by staining for CD45.1 and CD45.2 in blood
cells using FITC-conjugated anti-CD45.1 and PE-conjugated anti-CD45.2. All
chimera mice used in this study had 95% reconstitution.
Isolation of Lamina Propria Cells
Colons were dissected, washed with ice-cold PBS supplemented with
antibiotics (penicillin plus streptomycin), and cut into small pieces. Colons
pieces were then incubated with RPMI medium supplemented with 3% FBS,
0.5 mM DTT, 5mM EDTA, and antibiotics at 37C for 30 min with gentle
shaking. After removing epithelial layer, the remaining colon segments were
incubated at 37C with RPMI medium containing 0.5% CollagenaseD (Roche)
and 0.05% DNase (Roche) for 30 min with gentle shaking. The supernatant
was passed through 70 mM cell strainer to isolate lamina propria cells..
Cancer Cell
NLRP12 Dampens Inflammation and TumorigenesisNF-kB Activity Assay
Nuclear p65 DNA binding activity was determined by ELISA-based NF-kB
activity assay (Cayman, Cat #10007889) according to manufacturer instruc-
tions. Briefly, 10 ml (5 mg) nuclear extract was incubated in 96-well ELISA plate
precoated with a specific dsDNA sequence containing NF-kB response
element. A primary antibody for NF-kB (p65) was then added that was
detected by a HRP-conjugated secondary antibody. Finally P65 activity was
measured as a colorimetric readout at 450 nm.
Statistical Analysis
Data are represented as mean ± standard deviation or standard error of the
mean. Statistical significance was determined by Student’s t test; p < 0.05
was considered statistically significant.
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